CAMBRIDGE, Mass. (AP) _ Blueprint Medicines Corp. (BPMC) on Wednesday reported a loss of $111 million in its first quarter.

The Cambridge, Massachusetts-based company said it had a loss of $2.11 per share.

The results exceeded Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for a loss of $2.15 per share.

The cancer drug developer posted revenue of $6.2 million in the period, also beating Street forecasts. Seven analysts surveyed by Zacks expected $4.8 million.

Blueprint Medicines shares have dropped 25% since the beginning of the year. The stock has fallen 26% in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BPMC at https://www.zacks.com/ap/BPMC

Automated Insights, source Associated Press News